^
Association details:
| Biomarker: | MYC expression + MYC rearrangement |
|---|---|
| Cancer: | Lymphoma |
| Drug Class: | Aurora kinase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
RECURRENCE OF THE 8Q24 REARRANGEMENT IN BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM AND ITS ASSOCIATION WITH IMMUNOBLASTOID CYTOMORPHOLOGY, MYC EXPRESSION, AND DRUG RESPONSE
Published date:
05/17/2018
Excerpt:
Specimens and clinical information from 154 patients diagnosed with BPDCN...Forty-one (38%) MYC+BPDCN (positive for rearrangement and expression) and 59 (54%) MYC-BPDCN (both negative) cases were identified….Inhibitors for bromodomain and extraterminal protein (BETis) and aurora kinases (AKis) inhibited CAL-1 growth more effectively than that of PMDC05.
